Eurofins strengthens its comprehensive food testing offering in Japan through the acquisition of QSAI Analytical Research Center Co., Ltd.

Luxembourg – (business wire)–Regulatory News:

Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in food testing and a global scientific leader in bioanalytical testing, agrees to acquire a majority stake in QSAI Analytical Research Center Ltd. announced that it has signed (“QARC”).

Founded in 2013 as a spin-off from QSAI’s R&D center, QARC has been consistently developing pesticide screening and other food testing capabilities for 20 years, serving a broad customer base in the food, wholesale and retail industries, institutions and governments. We provide services. QARC is recognized as one of the leading private pesticide testing laboratories in Japan, offering the largest portfolio of over 800 pesticide screening tests covering a variety of complex food matrices. QARC has laboratories in Fukuoka and Nagoya where he employs 80 people and is ISO/IEC 17025 and Ministry of Health, Labor and Welfare (MHLW) accredited.

The acquisition of QARC complements the Eurofins network’s extensive food testing capabilities with pesticide, veterinary drug, foreign material and sensory testing services. The acquisition further strengthens Eurofins’ presence in Japan and further strengthens the Eurofins network offering to food importers and exporters.

About Eurofins, the world leader in bioanalysis

Eurofins is the test of life. Eurofins is a world leader in contract research services for food, environmental, pharmaceutical and cosmetic testing, discovery pharmacology, forensics, advanced materials science and agricultural science. Eurofins is also a market leader in genomics specific testing and laboratory services, clinical research support, contract development and manufacturing of biopharmaceuticals. The group is also rapidly developing in highly specialized molecular clinical diagnostic tests and in vitro diagnostic products.

With over 61,000 staff across a decentralized entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to explore the safety, identity, composition and efficacy of a wide range of products. Assess authenticity, origin, traceability, and purity. We offer innovative clinical diagnostic testing services and in vitro diagnostic products.

The Group’s aim is to provide its customers with high quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support clients’ increasingly stringent quality and safety standards, the increasing demands of regulatory authorities and the requirements of healthcare professionals worldwide.

In 2020 and 2021, Eurofins has moved swiftly to meet the global challenge of COVID-19. We have done this by helping more than 20 million patients each month who may have been affected by the pandemic with our testing products and services, creating the ability to directly support working healthcare professionals. The front line of fighting viruses. The Group has established extensive PCR testing capabilities, conducted over 40 million of his tests in our own laboratories, supported the development of numerous vaccines, and his SAFER to ensure a safer environment. Established @WORK™ inspection, monitoring, and consulting programs. Travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and geographic reach. Through R&D and acquisitions, the Group utilizes the latest developments in the fields of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Eurofins Scientific shares are listed on the Euronext Paris stock exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

This document contains inside information for the purposes of Regulation (EU) 596/2014 of the European Parliament and of the European Council of 16 April 2014, until it is legally made widely available by Eurofins through an approved distribution channel. It contains.


This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of his Eurofins Scientific management as of the date of this release. These forward-looking statements are not guarantees of future performance and the forward-looking events described in this release may not occur. Eurofins Scientific disclaims any intention or obligation to update these forward-looking statements and estimates. All statements and estimates are based on information available to our management as of the date of publication, but we cannot guarantee their completeness or validity.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *